In recent years, more individuals have been delaying parenthood for various reasons. However, for couples where the female partner is over 35, approximately one-third encounter challenges conceiving due to declining fertility.
Researchers conducting an ongoing clinical trial have put forward preliminary findings suggesting that rapamycin, a drug commonly utilized to prevent organ transplant rejection, could potentially extend a woman’s fertile years by as much as five years.
The early results, although yet to undergo peer review, indicate promising outcomes from a small pilot study. Nevertheless, definitive conclusions must await the completion of the full clinical trial, expected in two years.
Studies in mice have previously shown that rapamycin possesses anti-aging properties, including benefits for fertility. Female gametes, or eggs, develop alongside specialized cells in the ovaries during fetal development, forming what are known as primordial follicles. These follicles remain dormant until puberty, when they are recruited for ovulation.
Throughout a woman’s reproductive years, the ovarian reserve—established early in life—gradually diminishes as follicles are utilized or degrade. This process accelerates with age, leading to menopause, typically occurring around age 51, although timing varies widely among individuals.
Premature menopause, which affects around 1% of women, can significantly impact fertility intentions. Delaying ovarian aging could potentially extend a woman’s reproductive lifespan, a prospect that rapamycin may facilitate.
Originally developed as an immunosuppressant for organ transplant patients, rapamycin has also shown promise in combating age-related conditions and diseases. Studies in mice suggest it can delay ovarian aging and prolong fertility by preserving the ovarian reserve.
Initial findings from a pilot study involving perimenopausal women aged 35-45 indicate that rapamycin could reduce ovarian aging by up to 20% without adverse effects. Participants received either rapamycin or a placebo for three months, with ovarian reserve monitored via transvaginal ultrasound and hormonal assays.
Women treated with rapamycin exhibited significantly fewer recruited follicles per menstrual cycle compared to their counterparts, suggesting a potential mechanism for preserving ovarian reserve.
While the initial study involved a small cohort, the promising results have paved the way for a larger-scale trial involving 1,000 participants. Confirmation of these findings could herald rapamycin as a viable treatment for delaying ovarian aging and extending fertility in women.
Furthermore, this research underscores the potential of repurposing existing drugs to address women’s health issues. Similar initiatives are underway at the University of Central Lancashire, exploring the use of diabetes medications to enhance uterine health and investigate ovarian cancer treatments.
As research advances, the prospect of extending fertility through pharmaceutical intervention offers hope for women facing reproductive challenges later in life.
Related Links:
